Beijing Foyou Pharma CO.(SH:601089)2024-08-20 07:37Group 1: Innovation Drug Development - The company is focusing on the development of innovative drugs, particularly small nucleic acid drugs, and has initiated one non-clinical study [1] - The N-ER platform is based on the company's independent research and development, aimed at discovering and delivering innovative small nucleic acid drugs [2] - The N-ER platform can benchmark against companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals [2] Group 2: Financial Performance - The gross margin for the pharmaceutical formulation and medical device sectors remained stable compared to 2023 [3] - The company's pharmaceutical formulation revenue for the first half of 2024 was approximately ¥1.54 billion [3] - The company plans to disclose its cash dividend ratio for 2024 in accordance with relevant regulations [4] Group 3: Market Strategy and Future Outlook - The company aims to accelerate the consistency evaluation of generic drugs and enter new fields such as innovative drugs and biotherapy [4] - The company is optimistic about the impact of national policies encouraging innovative drugs, which are expected to drive industry development [4] - The company will continue to explore opportunities in the domestic market, particularly in response to emerging demands [4]